Endogenous MMP-9 and not MMP-2 promotes rheumatoid synovial fibroblast survival, inflammation and cartilage degradation

Rheumatology (United Kingdom)

Volumn 53, Issue 12, 2014, Pages 2270-2279

  Xue, Meilang ^a   McKelvey, Kelly ^a   Shen, Kaitlin ^a   Minhas, Nikita ^a   March, Lyn ^b   Park, Sang Youel ^c   Jackson, Christopher J ^a  

^a Sutton Arthritis Laboratories   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c Chonbuk National University   (South Korea)

Author keywords

Cartilage degradation; Inflammation; Invasion; Matrix metalloproteinase 2 and 9; Migration; Proliferation; Rheumatoid arthritis; Survival; Synovial fibroblasts

Indexed keywords

COLLAGEN GEL; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT ENZYME; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

1,9 DIMETHYLMETHYLENE BLUE ASSAY; AGED; APOPTOSIS; ARTICLE; BIOASSAY; BRDU ASSAY; CARTILAGE DEGENERATION; CARTILAGE EXPLANT; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; JOINT DESTRUCTION; MALE; MTT ASSAY; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 84982292421     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu254     Document Type: Article

References (51)

1. Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev 2008;223:252-70.
2. Tchetverikov I, Lard LR, DeGroot J et al. Matrix metalloproteinases- 3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003;62:1094-9.
3. Cunnane G, Fitzgerald O, Hummel KM et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001;44:1744-53.
4. Konttinen YT, Ainola M, Valleala H et al. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann Rheum Dis 1999;58:691-7.
5. Xue M, March L, Sambrook PN, Jackson CJ. Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis. Arthritis Rheum 2007; 56:2864-74.
6. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73.
7. van den Steen PE, Grillet B, Opdenakker G. Gelatinase B participates in collagen II degradation and releases glycosylated remnant epitopes in rheumatoid arthritis. Adv Exp Med Biol 2005;564:45-55.
8. Charni-Ben Tabassi N, Desmarais S, Bay-Jensen AC et al. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthritis Cartilage 2008;16:1183-91.
9. Gearing AJ, Beckett P, Christodoulou M et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555-7.
10. McQuibban GA, Gong JH, Tam EM et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202-6.
11. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1b by matrix metalloproteinases: a novel caspase- 1-independent pathway of IL-1b processing. J Immunol 1998;161:3340-6.
12. Ahrens D, Koch AE, Pope RM, Stein-Picarella M, Niedbala MJ. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum 1996;39:1576-87.
13. Giannelli G, Erriquez R, Iannone F et al. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol 2004; 22:335-8.
14. Kim KS, Choi HM, Lee YA et al. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis. Rheumatol Int 2011;31:543-7.
15. Itoh T, Matsuda H, Tanioka M et al. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002;169:2643-7.
16. Hong JS, Greenlee KJ, Pitchumani R et al. Dual protective mechanisms of matrix metalloproteinases 2 and 9 in immune defense against Streptococcus pneumoniae. J Immunol 2011;186:6427-36.
17. Hot A, Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Ann Rheum Dis 2011;70:727-32.
18. Xue M, Jackson CJ. Autocrine actions of matrix metalloproteinase (MMP)-2 counter the effects of MMP-9 to promote survival and prevent terminal differentiation of cultured human keratinocytes. J Invest Dermatol 2008; 128:2676-85.
19. Altman R, Asch E, Bloch D et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-49.
20. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
21. Xue M, Thompson P, Kelso I, Jackson C. Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes. Exp Cell Res 2004;299: 119-27.
22. Korff T, Augustin HG. Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J Cell Sci 1999;112 (Pt 19):3249-58.
23. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986;883:173-7.
24. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986;261:2814-8.
25. Xue M, Chan YK, Shen K et al. Protease-activated receptor 2, rather than protease-activated receptor 1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritis. Arthritis Rheum 2012;64:88-98.
26. Zhang HG, Wang Y, Xie JF et al. Regulation of tumor necrosis factor alpha-mediated apoptosis of rheumatoid arthritis synovial fibroblasts by the protein kinase Akt. Arthritis Rheum 2001;44:1555-67.
27. Huber LC, Distler O, Tarner I et al. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 2006;45: 669-75.
28. Lefevre S, Knedla A, Tennie C et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 2009;15:1414-20.
29. Tolboom TC, van der Helm-Van Mil AH, Nelissen RG et al. Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. Arthritis Rheum 2005;52:1999-2002.
30. Neumann E, Riepl B, Knedla A et al. Cell culture and passaging alters gene expression pattern and proliferation rate in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 2010;12:R83.
31. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase- 9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
32. Dubois B, Masure S, Hurtenbach U et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 1999;104:1507-15.
33. Garg P, Rojas M, Ravi A et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol 2006;177:4103-12.
34. Chen J, Zhang XM, Xu Q. Involvement of lymphocytes with a Th1 cytokine profile in bone cell damage associated with MMP-9 production in collagen-induced arthritis. Inflamm Res 2004;53:670-9.
35. Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G. Neutrophil gelatinase B potentiates interleukin- 8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000;96:2673-81.
36. Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine 2010;77:201-5.
37. Cascao R, Rosario HS, Souto-Carneiro MM, Fonseca JE. Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev 2010;9:531-5.
38. Roman-Blas JA, Jimenez SA. Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis. Int Rev Immunol 2008;27:351-74.
39. Wu HT, Sie SS, Kuan TC, Lin CS. Identifying the regulative role of NF-kappaB binding sites within promoter region of human matrix metalloproteinase 9 (mmp-9) by TNF-alpha induction. Appl Biochem Biotechnol 2013;169:438-49.
40. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617-29.
41. Takaishi H, Kimura T, Dalal S, Okada Y, D'Armiento J. Joint diseases and matrix metalloproteinases: a role for MMP-13. Curr Pharm Biotechnol 2008;9:47-54.
42. Joronen K, Kahari VM, Vuorio E. Temporospatial expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in mouse antigen-induced arthritis. Histochem Cell Biol 2005;124:535-45.
43. Stickens D, Behonick DJ, Ortega N et al. Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development 2004;131:5883-95.
44. Mosig RA, Dowling O, DiFeo A et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet 2007;16:1113-23.
45. Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2006;14:839-48.
46. Zhang Y, Dong J, He P et al. Genistein inhibit cytokines or growth factor-induced proliferation and transformation phenotype in fibroblast-like synoviocytes of rheumatoid arthritis. Inflammation 2012;35:377-87.
47. Seemayer CA, Kuchen S, Kuenzler P et al. Cartilage destruction mediated by synovial fibroblasts does not depend on proliferation in rheumatoid arthritis. Am J Pathol 2003;162:1549-57.
48. Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005; 1755:37-69.
49. Bauvois B. New facets of matrix metalloproteinases MMP- 2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochim Biophys Acta 2012;1825:29-36.
50. Rao JS, Bhoopathi P, Chetty C, Gujrati M, Lakka SS. MMP-9 short interfering RNA induced senescence resulting in inhibition of medulloblastoma growth via p16INK4a and mitogen-activated protein kinase pathway. Cancer Res 2007;67:4956-64.
51. Bhoopathi P, Chetty C, Kunigal S et al. Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem 2008; 283:1545-52.